Back HCV Treatment

Janssen Discontinues Hepatitis C Drug Development Program

Janssen Sciences announced last week that it will stop further development of its experimental hepatitis regimen containing AL-335, odalasvir, and simeprevir, as the market is saturated with effective therapies. It will instead focus on hepatitis B, which is seldom cured with existing antiviral medications.


Read more: